Mixed Topics
News
Association Calls For Increased Oversight in Response to Reports of Possibly Counterfeit Botulinum Toxin
The ASDSA referenced investigations in Illinois and Tennessee in which suspected counterfeit neurotoxins were associated with individuals’...
News
CDC Investigating Adverse Events Related to Counterfeit, Mishandled Botulinum Toxin
Reactions have included blurry vision, double vision, drooping eyelids, difficult swallowing or breathing, and other symptoms of botulism.
News
Consider Skin Cancer, Infection Risks in Solid Organ Transplant Recipients
There are over 450,000 people with a solid organ transplant living in the United States.
News
Androgenetic Alopecia: Study Finds Efficacy of Topical and Oral Minoxidil Similar
A randomized, controlled, blinded study finds little difference between the two forms of the drug in promoting hair growth in men.
News
New Tool Helps Clinicians Detect Zoom Dysmorphia in Virtual Settings
Affected individuals may fear being misunderstood, judged, or ridiculed because of a perceived flaw in their appearance, Dr. George Kroumpouzos...
News
Look Beyond BMI: Metabolic Factors’ Link to Cancer Explained
A snapshot assessment of metabolic syndrome is inadequate to show an association with cancer risk over time, the authors of new research say.
News
Does worsening metabolic syndrome increase the risk of developing cancer?
Elevated trajectories of metabolic syndrome were associated with an elevated overall cancer risk.
News
TIL for Melanoma: What Are the Costs and Other Challenges to Getting It to Patients?
Doctors are prepared to advocate for insurance coverage of the newly approved therapy on a case-by-case basis.
News
Study Finds No Increased Cancer Risk With Spironolactone
Spironolactone, used off-label for several skin conditions in women, carries a warning about an increased tumor risk associated with high doses in...
Conference Coverage
No Increase in Autoimmune Risk Seen With GLP-1 Receptor Agonists and SGLT2 Inhibitors
Patients with type 2 diabetes prescribed GLP-1 receptor agonists or SGLT2 inhibitors did not have a greater risk of developing autoimmune disease...